Walleye Capital’s Medifast MED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,452
Closed -$16.6K – 6103
2026
Q2
$15.4K Buy
1,452
+1,451
+145,100% +$16.7K ﹤0.01% 4437
2026
Q1
$10 Buy
+1
New +$11 ﹤0.01% 4312
2025
Q4
– Sell
-29,940
Closed -$409K – 4905
2025
Q3
$409K Sell
29,940
-8,154
-21% -$114K ﹤0.01% 2784
2025
Q2
$535K Buy
38,094
+25,473
+202% +$335K ﹤0.01% 2590
2025
Q1
$170K Buy
+12,621
New +$190K ﹤0.01% 3380
2024
Q4
– Sell
-6,457
Closed -$124K – 5259
2024
Q3
$124K Sell
6,457
-5,017
-44% -$96.7K ﹤0.01% 4300
2024
Q2
$250K Sell
11,474
-25,176
-69% -$671K ﹤0.01% 4131
2024
Q1
$1.4M Buy
+36,650
New +$1.78M ﹤0.01% 2263
2023
Q4
– Sell
-3,377
Closed -$253K – 5287
2023
Q3
$253K Sell
3,377
-5,724
-63% -$508K ﹤0.01% 3378
2023
Q2
$839K Buy
+9,101
New +$810K ﹤0.01% 2000
2023
Q1
– Sell
-1,071
Closed -$119K – 4201
2022
Q4
$124K Sell
1,071
-19,234
-95% -$2.24M ﹤0.01% 2287
2022
Q3
$2.2M Buy
+20,305
New +$2.91M 0.04% 506
2021
Q2
– Sell
-1,482
Closed -$314K – 1447
2021
Q1
$314K Buy
+1,482
New +$355K 0.02% 735
2020
Q4
– Sell
-1,458
Closed -$240K – 1035
2020
Q3
$240K Buy
+1,458
New +$240K 0.03% 561
2019
Q3
– Sell
-240
Closed -$31K – 2108
2019
Q2
$31K Buy
+240
New +$33.3K ﹤0.01% 1465

Other funds holding MED

Walleye Capital's MED Position: Q3 2026 in Review

Walleye Capital sold out of Medifast (MED) in Q3 2026, closing a stake of 1,452 shares — an estimated $16.6K sold.

Walleye Capital first reported a position in MED in Q2 2019 and held it in 15 quarters. The position peaked at $2.2M in Q3 2022. 96 funds tracked by Wall St. Rank hold MED as of Q3 2026.

  • Walleye Capital reported no remaining Medifast position as of Q3 2026 after selling out during the quarter.
  • Walleye Capital sold 1,452 Medifast shares in Q3 2026, an estimated $16.6K.
  • Walleye Capital first reported a position in Medifast in Q2 2019 and held it in 15 quarters.
  • Walleye Capital's Medifast position peaked at $2.2M in Q3 2022.
  • 96 funds tracked by Wall St. Rank held Medifast as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.